Tag Archives: HIV1

Long-acting cabotegravir, rilpivirine noninferior in HIV-1

(HealthDay)—For patients with HIV-1 suppression, long-acting cabotegravir plus rilpivirine is noninferior to oral therapy with dolutegravir-abacavir-lamivudine and standard oral therapy, according to two studies published online March 4 in the New England Journal of Medicine. Chloe Orkin, M.D., from the Queen Mary University of London, and colleagues conducted a phase …

Read More »
120*600 120*600